Compare TransMedics Group Inc (TMDX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vertiv Holdings Co — how do they compare? TransMedics Group Inc trades at $79.33 (market cap $2.81B), while Vertiv Holdings Co trades at $247.17 (market cap $94.90B). The key difference: Vertiv Holdings Co is far larger — about 33.8× TransMedics Group Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vertiv Holdings Co for 39 Days on average.
| TMDX | VRT | |
|---|---|---|
Market Cap | $2.81B | $94.90B |
Volume | 962,415 | 5,469,277 |
Sector | Health | Industrials |
52-Week High | $150.42 | $376.23 |
52-Week Low | $61.99 | $149.83 |
Typical Hold Time | 24 Days | 39 Days |
Enterprise Value | $3.21B | $95.12B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Vertiv (VRT) trades at $246.49, down 2.63% amid bearish technical signals but maintains strong fundamental momentum with consistent earnings beats and robust AI-driven data center demand. The stock shows elevated valuation multiples (P/E 55.77, P/S 8.42) against impressive profitability (ROE 43.94%, net margin 15.09%), while analyst consensus remains overwhelmingly bullish with a $364.94 price target. Recent news highlights Vertiv's strategic positioning in AI infrastructure cooling solutions.
Outlook remains positive given Vertiv's exposure to the $7.6 trillion AI spending boom (Goldman Sachs, Sep 2026), though risks include potential securities law investigations and competitive pressures. The stock offers growth exposure to data center electrification trends, with Q3 2026 earnings (expected EPS $1.82) serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
